Results 151 to 160 of about 25,303 (250)

Clinical and demographic profiles of people not meeting LDL-C goals after treatment with a proprotein convertase subtilisin/kexin type 9 inhibitor. [PDF]

Am J Prev Cardiol
Wang L, Murdock DJ, Sanchez RJ, Gu J.
europepmc   +1 more source

Design, Synthesis, and Characterization of Dichlorobiphenyl-Derived Inhibitors of the Proprotein Convertase Furin. [PDF]

J Med Chem
Lange RW, Boller C, Loresch M, Bloch K, Böttcher-Friebertshäuser E, Brandstetter H, Dahms SO, Steinmetzer T.   +7 more
europepmc   +1 more source

Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse

, 2018
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduces low-density lipoprotein cholesterol levels and improves cardiovascular outcomes.
Virani, Salim S., Ballantyne, Christie M, Saeed, Anum, Jones, Peter H, Nambi, Vijay   +4 more
core  

Clinical Outcomes of Early Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in East Asian Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Alqhtani S, Abid H, Almatrafi M, Bamehriz A, Alqurashi S, Alkhiri A, Alqhtani N, Sindi G, Bin Salama K, Alzahrani F, Alhazzani A.   +10 more
europepmc   +1 more source

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis. [PDF]

Sci Rep
Dermiki-Gkana F, Gravel CA, Kontogiorgis C, Douros A.   +3 more
europepmc   +1 more source

LDL receptor-independent mechanisms of proprotein convertase subtilisin/kexin type 9 in cardiovascular pathophysiology. [PDF]

Front Cardiovasc Med
Su H, Guo X, Li Q, Yuan X, Wu X, Zhao Z, Kan Y, Yang Y, Fu Z, Qi Z, Song G.   +10 more
europepmc   +1 more source

Polymorphisms in the proprotein convertase subtilisin/kexin type 9 gene in clinically diagnosed patients with familial hypercholesterolemia. [PDF]

Rev Assoc Med Bras (1992)
Costa ALDS, Santos JED, Salgado Junior W, Bertoncini-Silva C, Bizari L, Moura GSPL, Liberatore Junior RDR, Zorzo RA, Suen VMM.   +8 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerotic Plaque Progression: A Systematic Review and Meta-Analysis of Intravascular Imaging Studies. [PDF]

Rev Cardiovasc Med
Theofilis P, Vlachakis PK, Karakasis P, Iliakis P, Pamporis K, Oikonomou E, Dimitriadis K, Tsioufis K, Tousoulis D.   +8 more
europepmc   +1 more source

Clinical effect of proprotein convertase subtilisin/kexin type 9 inhibition in patients undergoing coronary artery bypass surgery. [PDF]

JTCVS Open
Nasso G, Marchese A, Santarpino G, Vignaroli W, Calabrese V, Taverna G, Larosa C, Bartolomucci F, Fiore F, Brigiani MS, Contegiacomo G, Greco E, Speziale G.   +12 more
europepmc   +1 more source

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Immune-Inflammatory Responses in the Acute Phase of Ischemic Stroke. [PDF]

J Inflamm Res
Li Z, Sun C, Zhang Q, Ji L, Zhang Y, Li S, Gu M, Gao J, Huang Z, Wang M, Zhou J, Zhu L, Jiang T, Zhou Q, Deng Q.   +14 more
europepmc   +1 more source